Evaluation of effectiveness and tolerability of a moisturiser as an adjuvant to isotretinoin therapy for acne: a real-world evidence
Keywords:Acne vulgaris, Dermocosmetic, Moisturiser, Retinoids, Psychological, Side-effect
Background: Moisturizers are recommended as an adjuvant to acne therapies especially topical/systemic retinoids to counteract their cutaneous side-effects. Moisturisers also reduce inflammation and the intensity of acne. The compliment study was designed to evaluate effectiveness and tolerability of moisturiser (Excela, Cipla Ltd., Mumbai, India) in patients prescribed isotretinoin for managing their acne in real-world scenario.
Methods: This open-label, observational, prospective, non-comparative multicentre study was conducted between June 2019 and January 2020. Patients who were prescribed Excela moisturiser as an adjuvant to isotretinoin for acne management were enrolled. After four weeks, the investigator graded the patient’s skin on smoothness and softness on a five-point scale and dryness, scaling and redness on a four-point scale. Its organoleptic characteristics and tolerability were evaluated using the subject assessment questionnaire.
Results: We enrolled 200 patients (average age: 24.02±5.44 years). Investigators rated smoothness and softness of the skin as very good to excellent in 129 (64.5%) and 113 (56.5%) patients. No patient reported severe skin dryness, scaling or redness. Very good to excellent spreadability and appeal was rated by 132 (66.0%) and 133 (66.5%) patients, respectively. Eighty (40%) patients rated the moisturiser as non-greasy/non-sticky. Itching (1%), redness (0.5%), cold (0.5%), and cough (0.5%) were reported as adverse events but were of mild intensity and unrelated to the study product. No patient experienced serious adverse event or moisturiser-related adverse event.
Conclusions: Overall, Excela moisturiser was effective and tolerable in patients with acne who were prescribed isotretinoin at the end of 4-week-long treatment period.
Bettoli V, Guerra-Tapia A, Herane MI, Piquero-Martín J. Challenges and Solutions in Oral Isotretinoin in Acne: Reflections on 35 Years of Experience. Clin Cosmet Investig Dermatol. 2019;12:943-51.
Sevimli Dikicier B. Topical treatment of acne vulgaris: efficiency, side effects, and adherence rate. J Int Med Res. 2019;47(7):2987-92.
Dréno B, Layton A, Zouboulis CC, López-Estebaranz JL, Zalewska-Janowska A, Bagatin E, et al. Adult female acne: a new paradigm. J Eur Acad Dermatol Venereol. 2013;27(9):1063-70.
Dréno B, Thiboutot D, Gollnick H, Finlay AY, Layton A, Leyden JJ, et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol. 2010;49(4):448-56.
Ip A, Muller I, Geraghty AWA, McNiven A, Little P, Santer M. Young people's perceptions of acne and acne treatments: secondary analysis of qualitative interview data. Br J Dermatol. 2020;183(2):349-56.
Thiboutot D, Del Rosso JQ. Acne vulgaris and the epidermal barrier: is acne vulgaris associated with inherent epidermal abnormalities that cause impairment of barrier functions? do any topical acne therapies alter the structural and/or functional integrity of the epidermal barrier?. J Clin Aesthet Dermatol. 2013;6(2):18-24.
de Lucas R, Moreno-Arias G, Perez-López M, Vera-Casaño Á, Aladren S, Milani M, et al. Adherence to drug treatments and adjuvant barrier repair therapies are key factors for clinical improvement in mild to moderate acne: the ACTUO observational prospective multicenter cohort trial in 643 patients. BMC Dermatol. 2015;15(1):17.
Araviiskaia E, Lopez Estebaranz JL, Pincelli C. Dermocosmetics: beneficial adjuncts in the treatment of acne vulgaris. J Dermatol Treat. 2021;32(1):3-10.
Zhao J, Wang Y, Jiang L, Mu Y-Z. The application of skin care product in acne treatment. Dermatol Ther. 2020;33(6):e14287.
Lynde CW, Andriessen A, Barankin B, Gannes GD, Gulliver W, Haber R, et al. Moisturizers and Ceramide-containing Moisturizers May Offer Concomitant Therapy with Benefits. J Clin Aesthet Dermatol. 2014; 7(3):18-26.
Dréno B, Araviiskaia E, Kerob D, Andriessen A, Anfilova M, Arenbergerova M, et al. Nonprescription acne vulgaris treatments: Their role in our treatment armamentarium-An international panel discussion. J Cosmet Dermatol. 2020;19(9):2201-11.
Gollnick HP. From new findings in acne pathogenesis to new approaches in treatment. J Eur Acad Dermatol Venereol. 2015;29(5):1-7.
Zhen Y, Stoudemayer M, Vamvakias G, Kligman AM. Pilot investigation of the hydrating effects of topical acne medications. J Drugs Dermatol. 2007;6(8):810-6.
Laquieze S, Czernielewski J, Rueda MJ. Beneficial effect of a moisturizing cream as adjunctive treatment to oral isotretinoin or topical tretinoin in the management of acne. J Drugs Dermatol. 2006;5(10): 985-90.
Monfrecola G, Capasso C, Russo G, Fabbrocini G. UV-selective face cream (Acne RA-1,2) in acne patients: clinical study of its effects on epidermal barrier function, sebum production, tolerability and therapy adherence. G Ital Dermatol Venereol. 2018; 153(1):26-32.
Nast A, Dréno B, Bettoli V, Bukvic Mokos Z, Degitz K, Dressler C, et al. European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version. J Eur Acad Dermatol Venereol. 2016;30(8): 1261-8.
Bagatin E, Costa CS, Rocha MADd, Picosse FR, Kamamoto CSL, Pirmez R, et al. Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermatology. Anais Brasileiros de Dermatol. 2020; 95:19-38.
Waldman A, Bolotin D, Arndt KA, Dover JS, Geronemus RG, Chapas A, et al. ASDS Guidelines Task Force: Consensus Recommendations Regarding the Safety of Lasers, Dermabrasion, Chemical Peels, Energy Devices, and Skin Surgery During and After Isotretinoin Use. Dermatol Surg. 2017;43(10):1249-62.
Del Rosso JQ. The role of skin care as an integral component in the management of acne vulgaris: part 1: the importance of cleanser and moisturizer ingredients, design, and product selection. J Clin Aesthet Dermatol. 2013;6(12):19-27.
McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002;288(22):2868-79.
Tan J, Bissonnette R, Gratton D, Kerrouche N, Canosa JM. The safety and efficacy of four different fixed combination regimens of adapalene 0.1%/benzoyl peroxide 2.5% gel for the treatment of acne vulgaris: results from a randomised controlled study. Eur J Dermatol. 2018;28(4):502-8.
Chularojanamontri L, Tuchinda P, Kulthanan K, Varothai S, Winayanuwattikun W. A double-blinded, randomized, vehicle-controlled study to access skin tolerability and efficacy of an anti-inflammatory moisturizer in treatment of acne with 0.1% adapalene gel. J Dermatol Treat. 2016;27(2):140-5.
Hayashi N, Kawashima M. Study of the usefulness of moisturizers on adherence of acne patients treated with adapalene. J Dermatol. 2014;41(7):592-7.
Del Rosso JQ, Brandt S. The Role of Skin Care as an Integral Component in the Management of Acne Vulgaris: Part 2: Tolerability and Performance of a Designated Skin Care Regimen Using a Foam Wash and Moisturizer SPF 30 in Patients with Acne Vulgaris Undergoing Active Treatment. J Clin Aesthet Dermatol. 2013;6(12):28-36.
Matsunaga K, Leow YH, Chan R, Kerrouche N, Paliargues F. Adjunctive usage of a non-comedogenic moisturizer with adapalene gel 0.1% improves local tolerance: a randomized, investigator-blinded, split-face study in healthy Asian subjects. J Dermatol Treat. 2013;24(4):278-82.
Munehiro A, Murakami Y, Shirahige Y, Nakai K, Moriue T, Matsunaka H, et al. Combination effects of cosmetic moisturisers in the topical treatment of acne vulgaris. J Dermatol Treat. 2012;23(3):172-6.
Herane MI, Fuenzalida H, Zegpi E, De Pablo C, Espadas MJ, Trullás C, et al. Specific gel-cream as adjuvant to oral isotretinoin improved hydration and prevented TEWL increase a double-blind, randomized, placebo-controlled study. J Cosmet Dermatol. 2009;8(3):181-5.